Anixa Biosciences, Inc. (ANIX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-99.1%

$0.03

vs $2.99 price

Levered DCF

$0.03

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

7.94

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-12.15×	-8.97×	-9.88×	-12.44×	-11.31×	-4.48×	-6.34×	-5.13×
P/B	8.84×	5.58×	4.02×	5.86×	4.1×	5.23×	14.63×	13.13×
P/S	0×	0×	466.18×	0×	284.11×	0×	306.35×	64.16×
EV / EBITDA	-12.1×	-8.74×	-9.83×	-11.51×	-8.92×	-3.94×	-6.64×	-4.92×
Gross margin	0.0%	0.0%	23.3%	0.0%	24.8%	0.0%	33.5%	1.7%
Operating margin	0.0%	0.0%	-5243.3%	0.0%	-2565.6%	0.0%	-4756.0%	-1232.0%
Net margin	0.0%	0.0%	-4671.9%	0.0%	-2528.6%	0.0%	-4658.8%	-1258.1%
Current ratio	8.08×	8.54×	12.5×	14.83×	28.35×	7.88×	4.11×	4.38×
Debt / equity	0.01×	0.01×	0.01×	0.01×	0.01×	0.01×	0×	0×
Interest coverage	0×	0×	0×	-133.41×	-40,794.07×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-72.1%	-62.8%	-40.3%	-46.8%	-36.5%	-115.7%	-222.5%	-257.5%
Return on invested capital	-82.7%	-72.3%	-46.8%	-48.8%	-37.5%	-119.9%	-247.1%	-264.4%
Return on assets	-68.0%	-58.1%	-38.4%	-44.7%	-35.7%	-107.2%	-185.1%	-217.0%
Free cash flow yield	-5.4%	-6.6%	-6.3%	-3.8%	-3.4%	-13.5%	-6.4%	-6.0%
Earnings yield	-8.2%	-11.2%	-10.0%	-8.0%	-8.9%	-22.1%	-15.2%	-19.6%
Enterprise value	$133M	$110.6M	$97.2M	$158M	$116.6M	$39.4M	$73.1M	$68.3M
Net debt / EBITDA	0.09×	0.08×	0.07×	0.88×	2.21×	0.64×	0.32×	0.22×
Cash conversion cycle (days)	-1,673	0	2	0	-129	-941	-6,348	-94